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Background: Endometrial cancer is the most common gynaecological malignancy in women of developed
countries. Many risk factors implicated in endometrial cancer trigger inflammatory events; therefore, alterations in
immune response may predispose an individual to disease. Toll-like receptors (TLRs) and nucleosome-binding
oligomerization domain (NOD) genes are integral to the recognition of pathogens and are highly polymorphic. For
these reasons, the aim of the study was to assess the frequency of polymorphic variants in TLR and NOD genes in
an Australian endometrial cancer population.
Methods: Ten polymorphisms were genotyped in 191 endometrial cancer cases and 291 controls using real-time
PCR: NOD1 (rs2075822, rs2907749, rs2907748), NOD2 (rs5743260, rs2066844, rs2066845), TLR2 (rs5743708), TLR4
(rs4986790) and TLR9 (rs5743836, rs187084).
Results: Haplotype analysis revealed that the combination of the variant alleles of the two TLR9 polymorphisms,
rs5743836 and rs187084, were protective for endometrial cancer risk: OR 0.11, 95% CI (0.03-0.44), p = 0.002. This
result remained highly significant after adjustment for endometrial cancer risk factors and Bonferroni correction for
multiple testing. There were no other associations observed for the other polymorphisms in TLR2, TLR4, NOD1 and
NOD2.
Conclusions: The variant ‘C’ allele of rs5743836 causes greater TLR9 transcriptional activity compared to the
‘T’ allele, therefore, higher TLR9 activity may be related to efficient removal of microbial pathogens within the
endometrium. Clearly, the association of these TLR9 polymorphisms and endometrial cancer risk must be further
examined in an independent population. The results point towards the importance of examining immune
response in endometrial tumourigenesis to understand new pathways that may be implicated in disease.
Background
Endometrial cancer represents a significant burden on
society as it is the most common gynaecological malig-
nancy diagnosed in women of developed countries [1-3].
Extensive analysis of the reproductive and environmen-
tal factors implicated in disease has been undertaken,
revealing that excessive/unopposed estrogen is the
major risk factor for disease; however, the genetic events
underlying the development and progression of
endometrial cancer are not well understood [4]. In 2005,
Modugno et al. proposed that inflammation may play a
role in the development of endometrial cancer [5]. This
hypothesis was based on the observation that the men-
strual cycle resembles an inflammatory process and that
risk factors associated with endometrial cancer such as
early menstruation, late menopause and exposure to
unopposed estrogens, may increase exposure to inflam-
matory events [5]. Support for altered immune response
in endometrial cancer is also evident in a number of
other related diseases such as endometrial hyperplasia, a
precursor to endometrial cancer development, and in
endometriosis, a common benign gynaecological
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between inflammation and cancer [8], therefore, indivi-
dual differences in response to inflammation may alter
the risk of developing endometrial cancer.
The maintenance of the immune response is impor-
tant for the recognition and subsequent response to a
wide range of microbial pathogens [9]. To determine
differences between the pathogen associated molecular
patterns (PAMPs) of these microbes, the innate immune
system uses specific pattern recognition receptors
(PRRs) to elicit an immune response [9]. Two specific
examples of PRRs are: toll-like receptors (TLRs) and
intracellular nucleosome-binding oligomerisation
domain (NOD) proteins.
The TLR family consists of 10 membrane-bound pro-
teins that respond to microbes in the extracellular
matrix [10] whereas the NOD proteins, NOD1 and
NOD2, recognise microbial pathogens located in the
cytoplasm [11]. Polymorphic variants in these genes
have been studied in a number of inflammatory diseases
and cancer however their association with endometrial
cancer remains elusive. With respect to the TLRs, TLR2,
TLR4 and TLR9 are highly polymorphic and represent
interesting targets to elucidate their role in endometrial
cancer development [12]. TLR2 recognises PAMPs from
aw i d er a n g eo fp a t h o g e n s ;TLR4 is involved in the
recognition of bacterial lipopolysaccharide (LPS) and
TLR9 recognises unmethylated CpG motifs present in
bacterial DNA and intracellular antigens [10,13,14].
Furthermore, NOD1 and NOD2 are involved in the
recognition of many bacterial pathogens and their acti-
vation signals the transcription of many pro-inflamma-
tory genes following NF-B activation [11]. Genetic
variants in NOD1 and NOD2, have been associated with
Crohn’s disease and other inflammatory disorders [11].
The aim of this study was to examine 10 polymorph-
isms in NOD1 (rs2075822, rs2907749 and rs2907748),
NOD2 (rs5743260, rs2066844 and rs2066845), TLR2
(rs5743708), TLR4 (rs4986790) and TLR9 (rs5743836
and rs187084) to determine whether there was any asso-




The study population has been previously described
[15-17]. This study initially consisted of 213 consecu-
tively recruited women with histologically confirmed
endometrial cancer who presented for treatment at the
Hunter Centre for Gynaecological Cancer, John Hunter
Hospital, Newcastle, New South Wales, Australia
between the years 1992 and 2005. Women that had
additionally been diagnosed with breast cancer were
excluded from this study.
The final analysis included 191 endometrial cancer
patients. Data on reproductive and environmental risk
factors including ethnicity, body mass index (BMI),
diabetes, high blood pressure (HBP), age of diagnosis
of endometrial cancer, age of menarche, age of meno-
pause, other personal cancer history, family cancer his-
tory (Family history of cancer was defined as cancer in
the index patient plus one or more 1st or 2nd degree
relatives diagnosed with cancer), parity, breastfeeding,
oral contraceptive use, chemotherapy, radiotherapy,
hormone therapy (HT), smoking and alcohol use was
collected using self reported questionnaires. Informa-
tion regarding recurrence, stage, grade and histology of
endometrial cancer was collected from their medical
records.
The control population consisted of 291 women that
were recruited between the years 2004 and 2005 for the
Hunter Community Study. This study aims to identify
genetic and environmental factors associated with ageing
in a cohort of individuals obtained from the Hunter
region, Newcastle, New South Wales, Australia. Any
control that had a prior diagnosis of either breast or
endometrial cancer was excluded from the study. Con-
trols were matched to cases by sex and age.
All participants provided informed written consent
prior to participation in this study. Ethics approval was
obtained from the Human Research Ethics Committee,
University of Newcastle, New South Wales, Australia
(H-050-0605) and the Hunter Area Research Ethics
Committee, Hunter New England Health Service, New-
castle, New South Wales, Australia (05/03/09/3.14).
DNA Isolation
Genomic DNA was extracted from 10 ml EDTA blood
using the “salting-out” method [18].
Molecular Analysis
Genotyping of three NOD1 polymorphisms (rs2075822,
rs2907749 and rs2907748); three NOD2 polymorphisms
(rs5743260, rs2066844 and rs2066845), one TLR2 poly-
morphism (rs5743708), one TLR4 polymorphism
(rs4986790) and two TLR9 polymorphisms (rs5743836
and rs187084) was performed on an ABI PRISM® 7500
Real-Time PCR System (PE Applied Biosystems, Foster
City, CA), using primers and probes from the Assay-by-
Design service (Applied Biosystems). The primer and
probe sequences are available upon request. The assay
was performed under universal conditions as previously
described (Ashton et al., 2008). The genotyping results
were confirmed by a second laboratory research assis-
tant and 5% of the samples were re-genotyped with
100% concordance. Any sample where a genotype could
not be accurately assessed was re-genotyped. The overall
call rates were 100%.
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Power calculations were performed using Quanto (Ver-
sion 1.2.3, May 2007, http://hydra.usc.edu/GxE). The
calculations performed showed that the number of cases
and controls (ratio 1:1.52) in our cohort was large
enough to detect a significant, p < 0.05, 2-fold increased
risk (OR >2.0), with 80% power, assuming a dominant
genetic model, with a minor allele frequency of 6.5%.
Therefore, our study has a large enough sample size to
statistically demonstrate that significant OR values over
2.0 or below 0.5 provide a statistically robust result.
For each polymorphism, Hardy-Weinberg Equilibrium
(HWE) was calculated in the control group to check for
compliance using the Institute for Human Genetics,
statistics website, http://ihg2.helmholtz-muenchen.de/
cgi-bin/hw/hwa1.pl (Munich, Germany). To determine
differences in genotype frequencies and environmental
and reproductive risk factors between the cases and
controls, chi-squared (c
2) statistics, odds ratios (ORs)
and 95% confidence intervals (CI) were calculated using
unconditional logistic regression. Multivariate uncondi-
tional logistic regression was performed to determine if
any risk factors altered the significance of the genotype
frequency results. The risk factors taken into account
were: BMI (<25 kg/m
2 and ≥25 kg/m
2), diabetes (yes/
no), HBP (yes/no), HT (yes/no), personal history of can-
cer (yes/no), smoking (ever/never) and alcohol con-
sumption (ever/never). Other risk factors such as age of
menopause were not included in the analysis since this
information was not available for the controls.
The genotype frequencies of all polymorphisms were
compared in the case group stratified for the environ-
mental and reproductive risk factors by using chi-
squared (c
2) analysis and ORs and 95% CI were calcu-
lated using unconditional logistic regression. To avoid
chance findings due to multiple testing of the 10
polymorphisms and 16 environmental/reproductive risk
factors, Bonferroni correction was used and the signifi-
cance levels was lowered to p = 0.005 (p = 0.05/10) for
the 10 polymorphisms and p = 0.003 (p = 0.05/16) for
the 16 environmental factors.
T-tests were used to determine differences in the age
of diagnosis of endometrial cancer by genotype. Kaplan
Meier survival analysis was used to plot the cumulative
survival versus the patient’s age of diagnosis of endome-
trial cancer. By comparing the Kaplan-Meier survival
curves for each genotype, differences in the age of diag-
nosis of endometrial cancer by genotype were examined.
The Wilcoxon’s test was used to determine the signifi-
cance of observations from early ages of diagnosis, log-
rank test, which gives more weight to later ages and
Tarone-Ware test, which is an intermediate of the two
other tests were used to examine the homogeneity of
the survival curves. The polymorphisms that showed a
statistically significant difference between the genotypes
and the age of diagnosis of endometrial cancer for all
three statistical tests were further examined by a multi-
variate Cox regression model where the risk factors
listed above were incorporated into the analysis.
Haplotypes were estimated using SIMHAP [19]. Link-
age disequilibrium (LD) was tested applying Lewontin’s
D’ statistic using the pwld function in STATA. Associa-
tions of single haplotypes and combinations of haplo-
types with endometrial cancer risk were performed
using SIMHAP.
The significance levels of all tests were set at p < 0.05
and were two-sided. All statistical analysis was per-
formed with SIMHAP (Laboratory for Genetic Epide-
miology, Western Australian Institute for Medical
Research, Australia), Intercooled STATA 8.2 (Stata
Corp., College Station, TX, USA) and SPSS Version 15
(SPSS Inc. Chicago, IL, USA).
Results
Comparison of selected environmental and reproductive
risk factors between cases and controls
Cases and controls were different with respect to poten-
tial endometrial cancer risk factors, including HBP, dia-
betes, HT, alcohol consumption, personal history of any
cancer, personal history of ovarian cancer, cervical can-
cer and other cancers as previously described [15-17].
Hardy Weinberg Equilibrium (HWE) and Linkage
Disequilibrium (LD)
The distributions of the genotypes of all ten polymorph-
isms in NOD1, NOD2, TLR2, TLR4 and TLR9 among the
cases and controls did not deviate from HWE. The three
NOD1 polymorphisms were in high LD (D’ values;
rs2075822 + rs2907749 = 0.89, rs2075822 + rs2907748 =
0.88 and rs2907749 + rs2907748 = 1.00). In addition, the
NOD2 polymorphisms were in high LD (D’ values;
rs5743260 + rs2066844 = 1.00 and rs5743260 + rs2066845
= 1.00) however rs2066844 and rs2066845 were not in LD
(D’ = 0.2). None of the TLR polymorphisms were in high
LD. Three TLR combinations were in partial LD: TLR2
rs5743708 + TLR4 rs4986790, D’ = 0.61; TLR2
rs5743708 + TLR9 rs187084, D’ = 0.57; and TLR4
rs4986790 + TLR9 rs187084, D’ =0 . 5 7 .
Comparison of genotype, allele and haplotype
frequencies of polymorphisms among endometrial cancer
cases and controls
The allele and genotype frequencies were compared
between the cases and controls for the polymorphisms
in NOD1, NOD2, TLR2, TLR4 and TLR9 (see Table 1).
The only significant result was observed for TLR9
rs187084; allele T vs allele C: OR 0.675, 95% CI (0.478-
0.954), p = 0.025. After Bonferroni correction for
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(p value must be less than 0.005). Haplotype analysis
revealed that the combination of the variant alleles for
TLR9 rs187084 and rs5743836 were associated with a
significant decreased risk of endometrial cancer; TT vs
CC: OR 0.11, 95% CI (0.03-0.44), p = 0.002 (see Table
2). This result remained highly significant after adjust-
ment for endometrial cancer risk factors and Bonferroni
correction for multiple testing; TT vs CC: OR 0.10, 95%
CI (0.02-0.46), p = 0.003 (see Table 2).
Influence of Genetic and Environmental/Reproductive Risk
Factors on the Age of Diagnosis of Endometrial Cancer
Kaplan-Meier survival analysis and T-tests were used to
evaluate the influence of the NOD1, NOD2, TLR2, TLR4
and TLR9 polymorphisms on the age of diagnosis of
endometrial cancer. There was an age effect observed
for the NOD1 rs2075822 polymorphism. Individuals
with the heterozygous and variant genotypes combined
had a later age of diagnosis (65 years) in comparison to
those with the wild-type genotype (62 years): Log-Rank
Table 1 Genotype frequencies of polymorphisms in NOD1, NOD2, TLR2, TLR4 and TLR9 and endometrial cancer risk
Polymorphism Genotypes Cases n (%) Controls n (%) c
2 OR (95% CI) and p value
TT 119 (62.3) 176 (60.5)
NOD1 (rs2075822) TC 62 (32.5) 105 (36.1) 1.188
CC 10 (5.2) 10 (3.4) p = 0.497 (0.774-1.823) p = 0.432
TC+CC 72 (37.7) 115 (39.5)
AA 104 (54.5) 152 (52.2)
NOD1 (rs2907749) AG 68 (35.6) 118 (40.6) 1.156
GG 19 (9.9) 21 (7.2) p = 0.392 (0.759-1.761) p = 0.499
AG+GG 87 (45.5) 139 (47.8)
CC 114 (59.7) 168 (57.7)
NOD1 (rs2907748) CT 64 (33.5) 110 (37.8) 1.156
TT 13 (6.8) 13 (4.5) p = 0.400 (0.755-1.769) p = 0.505
CT+TT 77 (40.3) 123 (42.3)
CC 182 (95.3) 282 (96.9) 1.549
NOD2 (rs5743260) CT 9 (4.7) 9 (3.1) p = 0.359 (0.604-3.977) p = 0.363
TT 0 (0.0) 0 (0.0)
CC 178 (93.2) 263 (90.4) 0.928
NOD2 (rs2066844) CT 13 (6.8) 28 (9.6) p = 0.278 (0.407-2.116) p = 0.859
TT 0 (0.0) 0 (0.0)
GG 187 (97.9) 282 (96.9) 0.636
NOD2 (rs2066845) GC 4 (2.1) 9 (3.1) p = 0.508 (0.143-2.835) p = 0.553
CC 0 (0.0) 0 (0.0)
GG 177 (92.7) 275 (94.5) 1.190
TLR2 (rs5743708) GA 14 (7.3) 16 (5.5) p = 0.416 (0.501-2.826) p = 0.694
AA 0 (0.0) 0 (0.0)
AA 163 (85.3) 258 (88.7)
TLR4 (rs4986790) AG 25 (13.1) 31 (10.6) 1.098
GG 3 (1.6) 2 (0.7) p = 0.449 (0.573-2.101) p = 0.778
AG+GG 28 (14.7) 33 (11.3)
TT 85 (44.5) 116 (39.9)
TLR9 (rs5743836) TC 79 (41.4) 128 (44.0) 0.781
CC 27 (14.1) 47 (16.1) p = 0.581 (0.511-1.195) p = 0.255
TC+CC 106 (55.5) 175 (60.1)
TT 138 (72.25) 187 (64.3)
TLR9 (rs187084) TC 49 (25.65) 88 (30.2) 0.675
CC 4 (2.1) 16 (5.5) p = 0.076 (0.428-1.064) p = 0.091
TC+CC 53 (27.75) 104 (35.7)
NB: Χ
2 - Wild-type genotype versus heterozygous genotype versus homozygous variant genotype. Odds ratios for polymorphisms in NOD1, TLR4 and TLR9 were
calculated as follows: Wild Type genotype compared to combination of heterozygous and homozygous variant genotypes. Odds ratios for polymorphisms in
NOD2 and TLR2 were calculated as follows: Wild Type genotype compared to heterozygous genotype. All Odds Ratios were adjusted for age, BMI, diabetes, HBP,
history of cancer, HT, smoking and alcohol use.
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0.039. However, after stratifying the results for the
environmental/reproductive risk factors using Cox
regression, the results showed a similar trend but were
no longer statistically significant, p = 0.061.
Genotype frequencies in the cases stratified for
environmental/reproductive risk factors
This analysis focused on all of the polymorphisms in the
cases stratified for known environmental/reproductive
confounders. After the results were adjusted using Bon-
ferroni correction, no significant results were observed.
Discussion
Recent attention has been given to the role of TLRs and
NOD genes in inflammatory disorders and oncogenesis
[8] as these two receptor families interact with environ-
mental stimuli and elicit intracellular responses to
microbial pathogens. New insights into the role of these
genes in disease have the potential to provide new ave-
nues for treatment and to also identify individuals at
risk. Further to this, many of these genes harbour poly-
morphic variants that alter protein functionality and
over-representation of these risk alleles in a specific
population may point towards novel biological events
involved in disease initiation and progression. With
respect to endometrial cancer, variants in genes involved
in the innate immune response have not been investi-
gated, however, a recent study suggested that a number
of risk factors trigger inflammatory events and that an
altered inflammatory response may predispose an indivi-
dual to develop endometrial cancer [5]. For these rea-
sons, we sought to determine if genetic variation in a
number of TLRsa n dNOD genes (TLR2, TLR4, TLR9,
NOD1 and NOD2) were associated with risk of develop-
ing endometrial cancer. These polymorphisms were cho-
sen as they have been previously related to a number of
inflammatory diseases.
In the current study, we showed that the variant
alleles of the TLR9 polymorphisms, rs5743836 (C allele)
and rs187084 (C allele) combined, are associated with a
decreased risk of endometrial cancer. Even though the
CC subgroup harboured a small number of patients (2
cases and 21 controls), the association observed
remained highly significant following adjustment for
endometrial cancer risk factors and Bonferroni correc-
tion for multiple testing, indicating a true effect. These
results must be interpreted with caution due to the
group sizes and confirmed in an independent and larger
cohort. No other associations were observed for the var-
iants in the TLR2, TLR4, NOD1 or NOD2.
TLR9 belongs to the family of nucleic acid recognition
TLRs, specifically identifying DNA-containing unmethy-
lated CpG motifs in bacteria [13]. Activation of TLR9
leads to an increase in NF-B transcriptional activation,
allowing maturation of dendritic cells and release of
proinflammatory cytokines [20]. It has been suggested
that the TLR9 polymorphisms, rs5743836 and rs187084,
located in the promoter region, alter the functional ability
of TLR9 [21]. The variant alleles of these polymorphisms
can possibly modify the response to bacterial pathogens
thereby varying inter-individual disease susceptibility. A
r e c e n ts t u d yb yN get al. (2009), showed that following
either TNFa or lipopolysaccharide (LPS) stimulation,
TLR9 activity, for the rs5743836 polymorphism, was
greater for the C allele vector compared to the T allele
vector using luciferase reporter constructs [22]. In addi-
tion, they observed an increase in NF-B binding affinity
of the C allele, indicating that enhanced transcription of
NF-B results in greater release and production of pro-
inflammatory mediators. Contrary to the results reported
herein, this group observed an association between
increased incidence of premalignant gastric changes and
the C allele of the rs5743836 polymorphism, however, we
have shown that the high activity C allele of rs5743836 in
combination with the C allele of rs187084, appears to be
protective for endometrial cancer development. To date,
there is no functional data available for the rs187084
polymorphism but since it is also located in the promoter
region; it could alter the function of the promoter.
Clearly, functional analysis of the TLR9 rs187084 poly-
morphism needs to be performed.
Table 2 Haplotype Analysis of TLR9 rs187084 (T > C) and rs5743836 (T > C) and endometrial cancer risk
Gene Haplotype Cases n (%) Controls n (%) OR (95% CI) p value
TLR9 (rs187084 and rs5743836) TT 98 (51.3) 141 (48.5) 1.00 (reference)
CT 65 (34.0) 90 (30.9) 1.09 (0.75-1.57)adj^ p = 0.66
0.99 (0.75-1.31) p = 0.94
TC 26 (13.6) 39 (13.4) 1.07 (0.63-1.80)adj^ p = 0.76
0.92 (0.63-1.36) p = 0.68
CC 2 (1.1) 21 (7.2) 0.10 (0.02-0.46)adj^ p = 0.003
0.11 (0.03-0.44) p = 0.002
NB: Variant allele is underlined.
^ Odds Ratio adjusted for age, BMI, diabetes, HBP, history of cancer, HT, smoking and alcohol use.
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the T allele of TLR9 rs5743836 polymorphism was tran-
scribed more efficiently than the C allele, indicating
greater activity of the T allele rather than the C allele
[21], but as pointed out by Ng et al. (2009), assessing
basal levels may not be appropriate when studying a dis-
ease that may be influenced by exposure to bacterial
pathogens. The results of our study are however similar
to those observed by Novak and colleagues. They
showed that the T allele was associated with an
increased risk of atopic eczema (AE) whereas the C
allele was observed as protective for AE. Furthermore, a
study by Lazarus et al. (2003) revealed that the C allele
was associated with asthma [23]. Clearly, there are large
differences in allelic frequency of these polymorphisms
in a wide range of diseases and for this reason, further
studies are required to confirm these previous results
and the results presented herein.
Conclusions
The combination of the variant C alleles of TLR9
rs5743836 and rs187084 appears to be protective for
endometrial cancer and that the high activity C allele of
rs5743836 may allow a better response to pathogenic
microbes that present in the endometrium. This state-
ment must be interpreted with caution as the biological
mechanisms underlying altered immune response in
individuals harbouring these polymorphic variants must
be further interrogated. The results presented in this
study highlight that alterations in immune response
genes may vary an individual’s susceptibility to develop
endometrial cancer. Further studies examining genes
involved in the immune response pathway are warranted
and have the potential to identify new biological
mechanisms involved in endometrial cancer.
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